<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192569</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA015999-01</org_study_id>
    <secondary_id>ATAHC</secondary_id>
    <nct_id>NCT00192569</nct_id>
  </id_info>
  <brief_title>Australian Trial in Acute Hepatitis C</brief_title>
  <official_title>Australian Trial in Acute Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Australian Trial in Acute Hepatitis C (ATAHC)

      A prospective non-randomised dual arm longitudinal cohort of newly acquired hepatitis C
      infection into which participants will be enrolled and then followed at 3 monthly intervals
      over a 3 year period.

      All participants will be offered a 24 week course of pegylated interferon alfa 2a which will
      be commenced within 12 weeks of screening (patients coinfected with HIV will be offered 24
      weeks with pegylated interferon alfa 2a plus ribavirin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purposes of the study are:

        -  To enrol and follow-up a large group of people with acute hepatitis C infection to
           examine why some people naturally clear hepatitis C and some don't.

        -  To examine how many people become re-infected after having cleared hepatitis C and to
           look at why this happened.

      The study will also offer everyone taking part the option of undergoing a 6 month course of
      pegylated interferon alfa 2a (plus ribavirin if HIV coinfected) as treatment for hepatitis C.
      The purpose of this part of the study is:

      1. To examine whether treatment is effective in clearing the virus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of peg-interferon alpha 2a (and ribavirin for HIV/HCV coifection)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Natural history of acute hepatitis C</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be followed for natural history of newly acquired HCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alfa 2a</intervention_name>
    <description>PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly</description>
    <arm_group_label>Treated</arm_group_label>
    <other_name>pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (HIV conifected patients only)</intervention_name>
    <description>genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing &lt;75kg and 1200mg for patients weighing â‰¥ 75kg)
Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients &gt;16 years of age; Anti-HCV antibody positive within the
             previous 6 months; Anti-HCV antibody negative in the two years prior to the anti-HCV
             antibody positive result OR acute hepatitis (jaundice or ALT &gt; 10 XULN) within the 12
             months prior to the anti-HCV antibody results (where other causes of acute hepatitis
             are excluded); HCV RNA positive (for treatment group); Negative urine or blood
             pregnancy test (for women of childbearing potential; treated arm only); Informed
             consent

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breast feeding;Therapy with any systemic anti-viral,
             anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of
             steroids and radiation) &lt;6 months prior to the first dose of study drug; Any
             investigational drug &lt;6 weeks prior to the first dose of study drug; Positive test at
             screening for anti-HAV IgM Ab, anti-HBc IgM Ab; History or other evidence of a medical
             condition associated with chronic liver disease other than HCV (e.g., hemochromatosis,
             autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin
             exposures); History or other evidence of bleeding from esophageal varices or other
             conditions consistent with decompensated liver disease; Neutrophil count &lt;1500
             cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening; Serum creatinine level
             &gt;1.5 times the upper limit of normal at screening; Hgb&lt; 12g/dL in women or &lt; 13g/dL in
             men at screening (for patients who receive combination therapy with Pegylated
             interferon and ribavirin only); Male partners of women who are pregnant (for patients
             who receive combination therapy with Pegylated interferon and ribavirin only); History
             of a severe seizure disorder or current anticonvulsant use; History of immunologically
             mediated disease, chronic pulmonary disease associated with functional limitation,
             severe cardiac disease, major organ transplantation or other evidence of severe
             illness, malignancy, or any other conditions which would make the patient, in the
             opinion of the investigator, unsuitable for the study; History of thyroid disease
             poorly controlled on prescribed medications, elevated thyroid stimulating hormone
             (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any
             clinical manifestations of thyroid disease; Evidence of severe retinopathy (e.g. CMV
             retinitis, macula degeneration); Inability or unwillingness to provide informed
             consent or abide by the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kaldor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre in HIV Epidemiology and Clinical Research.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Dore, MB BS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre in HIV Epidemiology and Clinical Research.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407 Doctors</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House GP Practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirketon Road Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthWorks Health Centre</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelburg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>April 13, 2011</last_update_submitted>
  <last_update_submitted_qc>April 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor John Kaldor</name_title>
    <organization>National Centre in HIV Epidemiology and Clincial Research. University of New South Wales</organization>
  </responsible_party>
  <keyword>Acute Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

